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ABSTRACT
Radiotherapy is an essential component of cancer therapy. Despite advances in 
cancer genomics, the mutation signatures of radioresistant tumors have not yet been 
fully elucidated. To address this issue, we analyzed a unique set of clinical specimens 
from a uterine cervical cancer that repeatedly locally recurred after multiple rounds 
of radiotherapy. Exon sequencing of 409 cancer-related genes in the treatment-naïve 
tumor and the tumors that recurred after initial and secondary radiotherapy identified 
(i) activating mutations in PIK3CA and KRAS, and putative inactivating mutations in 
SMAD4, as trunk mutation signatures that persisted over the clinical course; and (ii) 
mutations in KMT2A, TET1, and NLRP1 as acquired mutation signatures observed only 
in recurrent tumors after radiotherapy. Comprehensive mining of published in vitro 
genomics data pertaining to radiosensitivity revealed that simultaneous mutations in 
KRAS and SMAD4, which have not been described previously in uterine cervical cancer, 
are associated with cancer cell radioresistance. The association between this mutation 
signature and radioresistance was validated by isogenic cell-based experiments. 
These results provide proof-of-principle for the analytical pipeline employed in this 
study, which explores clinically relevant mutation signatures for radioresistance, and 
demonstrate that this approach is worth pursuing with larger cohorts in the future.
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INTRODUCTION
Radiotherapy is an essential component of cancer 
therapy [1, 2]. In the field of radiotherapy, clinical 
management aimed at improving treatment precision has 
generally focused on delivering radiations to a defined 
tumor target [3]. On the other hand, in the biological 
context, the factors used clinically for optimization of 
treatment planning include tumor size, imaging features, 
and histopathological typing [3, 4]. The response of tumors 
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to radiotherapy varies even among tumors for which these 
factors are similar, highlighting the need for additional 
indices to improve prediction of tumor radiosensitivity.
Precision cancer medicine, which uses the genetic 
information of individual tumors to guide treatment, is 
currently emerging in the field of clinical oncology [5]. 
Advances in next-generation sequencing technologies 
have enabled the identification of multiple genetic 
alterations that make tumor cells responsive to molecularly 
targeted drugs [6–9]. However, the mutation signatures 
of tumors resistant to radiotherapy have not been fully 
elucidated. Such mutation signatures would contribute to 
facilitation of precision radiotherapy, enabling clinicians to 
stratify patients with radioresistant tumors into treatments 
with high-intensity radiation modalities, e.g., carbon ion 
radiotherapy [4].
To address this issue, we investigated the mutation 
signatures of a unique set of clinical specimens from a 
uterine cervical cancer that repeatedly locally recurred 
after multiple rounds of radiotherapy. Exon sequencing 
of 409 cancer-related genes in treatment-naïve and 
multiply-recurrent tumors revealed rare simultaneous 
mutations in KRAS and SMAD4. In addition, we validated 
the association between this mutation signature and 
radioresistance by performing meta-analysis of published 
in vitro data and isogenic cell-based experiments.
RESULTS
Mutation profiles of radioresistant tumors
To investigate mutation signatures associated 
with radioresistance, we analyzed a series of tumors 
collected from a patient with uterine cervical cancer 
who experienced repeated local recurrence after multiple 
rounds of curative radiotherapy (Table 1). Given that the 
5-year local control rate for uterine cervical cancer treated 
with curative radiotherapy is as high as >90%, this case 
is considered extremely radioresistant [10]. At the time 
of diagnosis, the patient was 34 years old and the FIGO 
stage was IB2. The tumor was positive for HPV-16. The 
pathological diagnosis (according to the UICC pTNM, 6th 
edition) was a mucinous adenocarcinoma of the uterine 
cervix, intestinal plus endocervical type, pT1b2N1MX, G2 
(R0, Stage IIIB). Surgery comprised radical hysterectomy 
and bilateral salpingo-oophorectomy. Lymphatic invasion, 
vascular invasion, and metastatic foci were observed in the 
right ovary. Adjuvant chemotherapy comprised six courses 
of mitomycin C (10 mg/body on Day 1), etoposide (80 mg/
body on Days 1, 3, and 5), and cisplatin (45 mg/body on 
Day 1). Radiotherapy for the first recurrence comprised 
external body radiotherapy (50 Gy in 25 fractions delivered 
to the whole pelvis, using the center-seal technique for 
the latter 20 Gy) and intracavitary brachytherapy (23 Gy 
delivered in 4 fractions). Radiotherapy for the second 
recurrence comprised interstitial brachytherapy (30 Gy 
delivered in 5 fractions). Radiotherapy for the third 
recurrence comprised interstitial brachytherapy (30 Gy 
delivered in 5 fractions).
Using the Ion AmpliSeq Comprehensive Cancer 
Panel (Thermo Fisher Scientific), we performed 
semiconductor-based next-generation sequencing of 
exons of 409 cancer-related genes in the treatment-naïve 
tumor (T1), recurrent tumor after initial radiotherapy (T2), 
recurrent tumor after secondary radioherapy (T3), and 
normal tissue of the uterine cervix (as a Control) (Table 1 
and Supplementary Figure 1). T2 and T3 were diagnosed 
as local recurrence based on the fact that pathological 
findings for T2 and T3 were consistent with T1.
After quality filtering, the number of sequencing 
reads per sample was 10.6 million (Supplementary 
Table 1). Average coverage depth was 616 reads per base 
(Supplementary Table 1). Somatic mutations and copy 
number variations (CNVs) were determined using the 
analytical workflow described in Identification of somatic 
mutations and CNVs in MATERIALS AND METHODS. 
In total, we identified 91 somatic non-synonymous 
mutations and 394 CNV regions.
T1 harbored the PIK3CA E545K mutation 
(Figure 1A and Supplementary Table 2). PIK3CA is the 
gene most frequently mutated in uterine cervical cancer 
(14−26% of cases), and E545K is one of three hotspots 
for activating mutations in this gene [11−13]. T1 also 
had a high frequency (i.e., 60%; 3/5) of single-nucleotide 
substitutions in cytosines preceded by thymines, a 
characteristic of APOBEC mutagenesis, which is the 
predominant source of mutations in uterine cervical 
cancer (Figures 1B and 2) [11, 12, 14]. These observations 
suggested that the genetic characteristics of the treatment-
naïve tumor were typical of uterine cervical cancer.
Interestingly, T1−T3 had mutations in KRAS and 
SMAD4 in common (Figure 1A and Supplementary Table 2). 
KRAS G12D is a well-studied oncogenic driver, whereas the 
co-occurrence of R361C and R361H in SMAD4 indicated 
biallelic inactivation of this tumor suppressor [15−18]. 
The persistence of these mutations in T1−T3 indicates 
that they played pivotal roles in the radioresistance that 
enabled survival of the tumor through repeated rounds of 
radiotherapy.
Mutations in KMT2A, TET1, and NLRP1 were 
present in both T2 and T3, but not in T1 (Figure 1A and 
Supplementary Table 2). In addition, amplification of 
PIK3CA and FGFR2 genes was observed in both T2 and 
T3, but not in T1. These observations suggest that the 
gene alterations are generated, or accumulated, as the 
tumor survives through the initial round of radiotherapy. 
Therefore, these gene alterations may be involved in 
acquisition of radioresistance.
The number of somatic mutations and CNVs in 
T1 and T2 was comparable, but was higher in T3 than 
in T2 (Figure 1A, 1C, 1D and Supplementary Table 1). 
Interestingly, T3 exhibited an unbiased spectrum of 
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single-nucleotide substitutions in contrast with T1 and T2 
(Figures 1B and 2). 
Association of simultaneous mutations in KRAS 
and SMAD4 with radioresistance
Among the identified somatic alterations, the 
simultaneous mutations in KRAS and SMAD4 caught our 
attention because (i) they have not been reported in uterine 
cervical cancers, and (ii) their persistence in T1−T3 indicates 
that this mutation signature contributed to the extreme 
radioresistance of the tumor. Hence, we investigated the 
association of this mutation signature with radiosensitivity 
in published in vitro data. Despite an intensive literature 
search, we were unable to identify uterine cervical cancer 
cell lines with simultaneous mutations in KRAS and SMAD4, 
supporting the idea that this mutation signature is rare among 
uterine cervical cancers. We then expanded our search to 
1039 cell lines derived from various cancers registered in the 
Cancer Cell Line Encyclopedia (CCLE). This comprehensive 
search identified 12 cell lines simultaneously carrying (i) 
gene amplification and/or putative driver mutations in 
KRAS and (ii) homozygous deletion or truncation mutations 
in SMAD4 (hereafter referred to as KRASmt/SMAD4mt cell 
lines) for which in vitro radiosensitivity has been assessed 
in clonogenic assays (Table 2). As a control, we randomly 
selected 12 cancer type–matched cell lines without 
simultaneous mutations in KRAS and SMAD4 (hereafter 
Table 1: Clinical course of the patient and timing of sample collection
Event Sample Treatment Months
Diagnosis T1 0
Normal Surgery 1
Adjuvant chemotherapy 3
Recurrence at vaginal stump 11
Radiotherapy (EBRT+ICBT) 13
Recurrence at vaginal stump T2 31
Radiotherapy (ISBT) 32
Recurrence at vaginal stump T3 46
Radiotherapy (ISBT) 47
Deceased 71
Abbreviations: EBRT, external body radiotherapy; ICBT, intracavitary brachytherapy; ISBT, interstitial brachytherapy. 
Treatment details are described in Supplementary Text.
Figure 1: Summary of somatic alterations in treatment-naïve and recurrent tumors. (A) Mutated genes, according to 
mutation type. Genes found to be mutated in T1−T3 are indicated in red. (B) Mutation spectrum of single-nucleotide substitutions. (C) 
Number of mutations. (D) Number of CNV regions.
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referred to as Control cell lines) for which published in 
vitro radiosensitivity data were available (Table 2). The 
prevalence of KRAS and SMAD4 mutations in the Control 
cell lines was 50% and 17%, respectively, whereas that 
in cancer type– and sample size–matched clinical tumor 
populations was 48% and 2.5%, respectively. This indicates 
that the randomly selected Control cell lines reflect the 
profiles of clinical tumors in terms of KRAS mutations, 
with a relatively high prevalence of SMAD4 mutations (for 
details, see Identification of KRASmt/SMAD4mt and Control 
cell lines in CCLE in MATERIALS AND METHODS) 
(Table 2 and Supplementary Table 3). The surviving fraction 
after exposure to 2-Gy irradiation, as assessed in clonogenic 
assays (SF2), is relevant with respect to the tumor response to 
radiotherapy; the precision of SF2 is sufficient for inter-assay 
comparison [19, 20]. Based on this evidence, we obtained 
all available SF2 data for the KRAS
mt/SMAD4mt and Control 
cell lines by performing a comprehensive literature search 
(for details, see Acquisition of SF2 data from the literature 
in MATERIALS AND METHODS) and compared SF2 
data between the two groups (Table 2 and Supplementary 
Table 4). We found that SF2 in the 12 KRAS
mt/SMAD4mt cell 
lines was significantly higher than in the 12 Control cell lines 
(P = 0.010) (Figure 3A), indicating that simultaneous 
mutations in KRAS and SMAD4 are associated with 
radioresistance.
Finally, we examined the association between the 
KRASmt/SMAD4mt signature and radioresistance measured 
in isogenic cell-based experimental systems. For these 
experiments, we used KRAS G12D-knock-in cells (SW48-
KRASG12D) treated with SMAD4-siRNA (siSMAD4) which 
mimics loss-of-function mutations in SMAD4, and the 
parental SW48 cell line (as the Control) (Table 2). We 
found that the SF2 values for siSMAD4-treated SW48-
KRASG12D cells were significantly higher than those 
for SW48 cells (P = 0.034) (Figure 3B and 3C). These 
data support an association between radioresistance and 
simultaneous mutations in KRAS and SMAD4.
DISCUSSION
The profiles of mutations that occur over the clinical 
course of cancer have been studied extensively in the 
context of recurrence after chemotherapy. For example, 
EGFR T790M is enriched after treatment with EGFR 
tyrosine kinase inhibitors, and this mutation contributes 
to resistance to this type of therapy [21]. Recently, diverse 
genetic branching was reported in spatiotemporally 
different tumors in a single patient [22]. From this 
perspective, the present study is the first to compare the 
mutation profiles of treatment-naïve tumors with those of 
multiply-recurrent tumors collected from the same disease 
site following multiple rounds of radiotherapy. Our results 
highlighted (i) activating mutations in PIK3CA and KRAS, 
and putative inactivating mutations in SMAD4, as trunk 
mutation signatures that persisted over the clinical course; 
and (ii) mutations in KMT2A, TET1, and NLRP1, and 
gene amplification of PIK3CA and FGFR2, as acquired 
mutation signatures observed only in recurrent tumors 
after radiotherapy. Comprehensive mining of published 
in vitro data revealed that simultaneous mutations in 
KRAS and SMAD4 are associated with cancer cell 
radioresistance. Although this was a pilot study that 
analyzed only one case, these data provide proof-of-
principle for the analytical pipeline that we employed, 
which explores clinically relevant mutation signatures 
for radioresistance, indicating that this approach is worth 
pursuing in larger cohorts in the future.
Several studies have demonstrated predictive 
biomarkers for radiosensitivity [23]. In many cases, 
radiosensitivity is predicted based on gene expression 
profiles of frozen tumor tissues, which are generally 
difficult to collect in routine clinical practice. Importantly 
in this regard, the KRASmt/SMAD4mt signature can 
be assessed using formalin-fixed paraffin-embedded 
(FFPE) tissues, which are routinely used for pathological 
diagnosis, indicating that this approach is suitable for 
Figure 2: Lego plots of mutational patterns in a three-base context. The somatic single-nucleotide variants identified in T1–3 
are categorized into six groups based on the base substitution type and are shown in different colors. Each group is further classified into 
16 subgroups based on the 5’ and 3’ neighboring bases [12, 14].
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application in the clinic. The predictive value of the 
KRASmt/SMAD4mt signature for radioresistance should be 
verified further in clinical studies.
To date, two large-scale whole-exome sequencing 
studies of uterine cervical cancer have been conducted to 
identify its genomic landscape [8, 9]. According to these 
studies, the genomic profiles of uterine cervical cancer are 
characterized by recurrent alterations in PIK3CA, EP300, 
FBXW7, PTEN, HLA-B, and KRAS (in 14−26%, 11−12%, 
10−11%, 7-8%, 6-8%, and 3–9% of cases, respectively), 
along with a predominant APOBEC mutagenesis pattern. 
Mutations in PIK3CA and KRAS have been studied using 
targeted sequencing approaches, which identified mutation 
frequencies comparable with those observed in whole-
exome sequencing studies [24−28]; while alterations in 
SMAD4 was identified in only one of the whole-exome 
sequencing study at 5% of cases [11]. Concomitant 
alterations in KRAS and SMAD4 have not been reported 
for uterine cervical cancer; indeed, data combined from 
different types of tumors suggest that such alterations are 
rare (i.e., 1.2%; 279/22928) (Supplementary Table 5 and 
Supplementary Figure 2). Nevertheless, it is noteworthy 
that pancreatic cancer, which is clinically radioresistant 
[29], shows the highest frequency of alterations (24%). 
Interestingly, a previous study demonstrates that treatment 
of hTERT-immortalized human pancreatic duct cells in 
which KRAS is overexpressed and SMAD4 is suppressed 
upregulates NF-kB [30]. Since NF-kB regulates multiple 
Table 2: KRASmt/SMAD4mt and Control cell lines
Cell line Group Cancer type KRAS SMAD4 SF2
AsPC-1 KRASmt/SMAD4mt pancreatic G12D HD 0.66 ± 0.13
PK-1 KRASmt/SMAD4mt pancreatic G12D HD 0.50
SW1990 KRASmt/SMAD4mt pancreatic G12D HD 0.56 ± 0.19
Capan-1 KRASmt/SMAD4mt pancreatic G12V S343* 0.52 ± 0.24
CFPAC-1 KRASmt/SMAD4mt pancreatic AMP, G12V HD 0.58
PSN1 KRASmt/SMAD4mt pancreatic AMP, G12R HD 0.48 ± 0.00
T84 KRASmt/SMAD4mt colorectal G12D HD 0.74 ± 0.28
SW403 KRASmt/SMAD4mt colorectal G13V HD 0.59
SW480 KRASmt/SMAD4mt colorectal AMP, G12V HD 0.67 ± 0.07
SW620 KRASmt/SMAD4mt colorectal AMP, G12V HD 0.59 ± 0.16
AGS KRASmt/SMAD4mt stomach G12D HD 0.45 ± 0.06
SW1573 KRASmt/SMAD4mt lung G12C HD 0.60 ± 0.08
Capan-2 Control pancreatic G12V WT 0.49 ± 0.04
MIAPaCa-2 Control pancreatic G12C WT 0.49 ± 0.10
PANC-1 Control pancreatic AMP WT 0.73 ± 0.20
HCT 116 Control colorectal G13D WT 0.42 ± 0.10
LoVo Control colorectal G13D WT 0.38 ± 0.10
LS180 Control colorectal G12D WT 0.50
RKO Control colorectal WT WT 0.33 ± 0.13
SW48 Control colorectal WT WT 0.22 ± 0.06
NCI-N87 Control stomach WT HD 0.39 ± 0.15
MKN-45 Control stomach WT HD 0.65 ± 0.25
NCI-H1437 Control lung WT WT 0.34
NCI-H1648 Control lung WT WT 0.16
Abbreviations: AMP, amplification; HD, homozygous deletion; WT, wild type. SF2 data were obtained from previous 
publications, and the average ± standard deviation (if available) value for each cell line is shown (for details, see 
Acquisition of SF2 data from the literature in MATERIALS AND METHODS).
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anti-apoptotic genes and is considered to be a major 
contributor to radioresistance [31], it is possible that 
simultaneous mutations in KRAS and SMAD4 (as observed 
in the present study) contributed to the radioresistant 
nature of the tumor via this mechanism.
KMT2A is a member of the KMT2 complex, which 
methylates lysine 4 on histone H3 (H3K4) to promote 
genome accessibility and transcription [32]. A recent study 
reports broad trimethylation of H3K4 in pan-cancer tumor 
suppressor genes, including TP53, in normal cells, and 
shortage of the trimethylation pattern in cancer cells in 
opposite [33]. In cancer, common mutations of KMT2A are 
nonsense, frameshift, and missense mutations; this suggests 
that KMT2A mutations observed in cancer contribute to 
loss-of-function of KMT2A [32], whereas suppression of 
TP53 contributes to resistance of cancer cells to X-rays 
[34]. Taken together, the evidence suggests that the KMT2A 
mutations observed herein might play roles in acquisition 
of radioresistance by tumor cells through loss-of-function 
of KMT2A, which contributes to suppression of TP53 and 
other tumor suppressor genes, transcription of which is 
regulated by methylation on H3K4.
TET1 is an enzyme that catalyzes successive 
oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, 
5-formylcytosine, and 5-carboxylcytosine to promote 
DNA demethylation [35]. Mutations in TET1 occur in 
a wide variety of solid tumors, albeit at relatively low 
frequency (0.1−10% of cases) [35]. However, we do not 
have solid evidence on how TET1 mutations contribute to 
onset and maintenance of tumors, and it is unclear whether 
TET1 mutations confer a selective advantage, or whether 
they represent inconsequential passenger mutations; this 
warrants further research [35].
Studies suggest that FGF2 upregulates expression 
of anti-apoptotic proteins such as BCL-2 by activating S6 
kinase within the PI3K-AKT signaling pathway, thereby 
promoting resistance to chemotherapy [36]. Amplification 
of PIK3CA and FGFR2 might contribute to acquisition 
of radioresistance by the tumor in the present study. In 
addition, amplification of PIK3CA and FGFR2 in T2 and 
T3, combined with activating mutations in KRAS and 
PIK3CA in T1−3, indicates a critical role for the RAS-
PI3K axis in tumor survival through multiple rounds of 
radiotherapy [37].
Several mutations detected in T1 or T2 were 
not detected in T3. It is possible that radiotherapy 
induces nucleotide modifications in these genes in some 
cancer cells, which was followed by clonal selection. 
Another possibility is that differences in the mutational 
profiles observed in these samples are based on genetic 
heterogeneity within the tumor, which was retained over 
the clinical course. Further studies are warranted.
The present study has the following limitations. 
First, we used a commercially available gene panel that 
contains only 409 cancer-related genes. Therefore, we 
were not able to investigate the mutational status of 
genes not listed in the panel. It should be noted that a 
number of mutations in genes not listed in the panel do 
occur in uterine cervical cancers [38]. Further studies 
based on whole-exome sequencing will help to identify 
the mutational signature associated with radioresistance 
in uterine cervical cancer. Second, we analyzed only one 
case, due to the rarity of patients who receive multiple 
rounds of radiotherapy at the same biopsy-accessible 
disease site. Third, we did not investigate the mechanisms 
underlying the radioresistance associated with the 
Figure 3: Higher SF2 is associated with simultaneous mutations in KRAS and SMAD4. (A, B) SF2 values (assessed in a 
clonogenic assay) for 12 KRASmt/SMAD4mt and 12 Control cell lines (obtained from the literature) (A) and those for siControl-treated 
SW48 and siSMAD4-treated SW48-KRASG12D cells (experiments were performed in quadruplicate) (B). Bars denote the mean ± standard 
deviation (for details, see Acquisition of SF2 data from the literature in MATERIALS AND METHODS and Supplementary Table 6). 
(C) Immunoblots showing expression of SMAD4 and β-actin (as a loading Control) in siControl-treated SW48 and siSMAD4-treated 
SW48-KRASG12D cells.
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KRASmt/SMAD4mt signature; we considered such an 
effort to be outside the scope of the present study, which 
primarily aimed to discover clinically applicable mutation 
signatures associated with radioresistance. Fourth, we 
diagnosed T2 and T3 as local recurrence based on the fact 
that pathological findings for T2 and T3 are consistent 
with those of T1. The fact that T1−T3 shared rare 
simultaneous mutations in KRAS and SMAD4 support the 
idea that T2 and T3 recurred from T1. Nevertheless, the 
possibility that T2 and T3 are secondary cancers distinct 
from T1 cannot be ruled out completely because there 
is no evidence so far, on the difference in mutational 
signatures between locally recurrent tumors and 
secondary tumors. Fifth, we did not analyze samples at 
first recurrence because our aim was to identify mutational 
signatures associated with radioresistance by comparing 
mutational profiles between treatment-naïve tumors 
and tumors that recurred after radiotherapy; therefore, 
analyzing samples from the first recurrence, which is a 
tumor that recurs after chemotherapy, was beyond the 
scope of the present study. Nevertheless, we confirmed the 
presence of mutations commonly detected in T1−T3, i.e., 
PIK3CA (E545K), KRAS (G12D), and SMAD4 (R361C 
and R361H), by Sanger sequencing of tumor samples from 
the first recurrence, indicating that this tumor also recurred 
from T1 and shares the trunk mutational characteristics 
with T2 and T3 (Supplementary Figure 3). Sixth, Sanger 
sequencing results for PIK3CA (c.1633G>A) and TET1 
(c.242G>A), in which mutations in T2 were not detected, 
should have been validated using other methods, including 
real-time polymerase chain reaction (PCR) and droplet 
digital PCR. However, we were not able to conduct these 
experiments due to a shortage of sample. Lastly, the T3 
specimen was smaller than the other specimens, which 
might affect smaller coverage for T3 compared to that for 
the others.
In summary, we identified rare simultaneous 
mutations in KRAS and SMAD4 in a series of tumors that 
survived multiple rounds of radiotherapy and validated 
the association between the mutation signature and 
radioresistance by conducting meta-analysis of published 
in vitro data and isogenic cell-based experiments. 
Based on this pilot study, we propose that our analytical 
pipeline would be useful for identification of clinically 
relevant mutation signatures of radioresistance, and that 
this approach warrants validation in larger cohorts. The 
predictive value of the KRASmt/SMAD4mt signature for 
radioresistance should also be evaluated in the clinic.
MATERIALS AND METHODS
Ethics
This study was approved by the Institutional Review 
Boards of Gunma University Hospital (approved number: 
1109). Written informed consent was obtained from the 
patient. The study was conducted in accordance with the 
ethical principles of the Declaration of Helsinki.
Tissue sample collection
Tumor tissues were collected by punch biopsy. 
Normal tissues of the uterine cervix were collected by 
surgery. The presence of malignant cells was pathologically 
confirmed in all tumor specimens, and the absence of 
malignant cells was likewise confirmed in the normal 
tissue specimen. 
DNA preparation
DNA was extracted from the FFPE tissues using 
the QIAamp DNA FFPE Tissue kit (Qiagen). The 
TaqMan RNase P Detection Reagents kit (Thermo Fisher 
Scientific) was used to quantify purified DNA.
Semiconductor-based next-generation 
sequencing
DNA (40 ng) was subjected to multiplex PCR 
amplification using an Ion AmpliSeq Comprehensive 
Cancer Panel that covers 95.4% of the exons of the 409 
cancer-related genes. Library preparation and sequencing 
with the Ion Torrent sequencer were performed as 
previously described [39–41]. The templates were 
sequenced after emulsion PCR with 6–8 samples per Ion 
PI chip using the Ion PI HI-Q Chef kit (Thermo Fisher 
Scientific).
Identification of somatic mutations and CNVs
Somatic mutations and CNVs were determined 
as previously described, with minor modifications [42]. 
Briefly, the sequenced data were aligned to the Genome 
Reference Consortium Human Build 37 (hg19), and reads 
were counted using Torrent Suite version 5.0 (Thermo 
Fisher Scientific). Single-nucleotide variants, insertions, and 
deletions were determined using the Ion Reporter software 
5.0 tumor-normal workflow (Thermo Fisher Scientific), in 
which germline variants were subtracted from the tumor 
variants. The following criteria were used as cutoffs: total 
coverage >20, variant coverage >10, variant frequency 
>5%, and minor allele frequency <0.1%. All identified 
single-nucleotide variants, insertions, and deletions were 
visually inspected using the Integrative Genomics Viewer 
software to filter out possible strand-specific errors, such as a 
mutation detected only in either the forward or reverse DNA 
strand [43]. The dbSNP database was used to exclude SNPs 
from the called variants. SIFT, Polyphen-2, and Grantham 
scores were used to estimate evolutionary conservation 
and the effects of amino-acid substitution on the structure 
and function of the protein. CNVs were determined with 
the Ion Reporter software using an algorithm based on a 
Hidden Markov Model. To verify the robustness of next-
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generation sequencing, Sanger sequencing was performed 
for the somatic non-synonymous mutations in PIK3CA, 
KRAS, and SMAD4 that were commonly identified in 
T1−T3, as well as for those in KMT2A, TET1, and NLRP1 
that were commonly identified in T2 and T3 but not in T1. 
As a result, the mutational status for 93.7% (30/32) of the 
samples analyzed was consistent with that observed after 
next-generation sequencing, demonstrating the robustness 
of the analytical workflow (Supplementary Figures 4 and 5).
Identification of KRASmt/SMAD4mt and Control 
cell lines in CCLE
The KRASmt/SMAD4mt and Control cell lines were 
identified based on genetic information in cBioportal 
for Cancer Genomics (Table 2) [44, 45]. The KRASmt/
SMAD4mt cell lines were derived from pancreatic, 
colorectal, stomach, and lung cancers. Control cell lines 
were selected randomly from CCLE, matching the cancer 
type to the KRASmt/SMAD4mt cell lines. Differences in the 
distribution of cancer types between the KRASmt/SMAD4mt 
and Control cell lines were not statistically significant 
(P = 0.68, as assessed by Fisher’s exact test). The 
prevalence of KRAS and SMAD4 mutations in clinical 
tumor specimens of pancreatic, colorectal, stomach, and 
lung cancer was confirmed using cBioportal for Cancer 
Genomics, and the combined prevalence of the mutations 
in the four cancer types was calculated by matching the 
relative proportion for each cancer type to those of the 
Control cell lines (Supplementary Table 3).
Acquisition of SF2 data from the literature
All published SF2 data for the KRAS
mt/SMAD4mt and 
Control cell lines were obtained as previously described 
[20]. Briefly, a PubMed search was performed for each 
cell line using the terms “[cell line name] AND (X-rays 
OR gamma rays OR radiation)”. Two radiation oncologists 
(EN and TBMP) examined all manuscripts identified by 
the search in their entirety, and identified publications 
reporting data obtained from clonogenic assays after 
treatment with X-rays or γ-rays alone. This examination 
identified 95 relevant papers, from which SF2 data were 
obtained (Table 2 and Supplementary Table 4). For each 
cell line, the average SF2 was calculated and used for 
analysis.
Cell culture
SW48 and SW48-KRASG12D cells were purchased 
from ATCC and cultured in DMEM (Gibco) supplemented 
with 10% fetal bovine serum (Sigma).
siRNA knockdown
Transfection of siRNA was performed using 
HiPerFect (Qiagen), as previously described [46]. Briefly, 
siSMAD4 (Thermo Fisher Scientific, 4390824) or Control-
siRNA (siControl, GGGAUACCUAGACGUUCUAdTdT; 
Sigma) was added to suspended cells after trypsinization. 
After 24 h, cells were trypsinized, suspended, and re-
transfected with the siRNAs. Cells were incubated for 
24 h after the second transfection and then subjected to 
clonogenic assay and immunoblotting (in parallel).
Clonogenic assay
The clonogenic assay was performed as previously 
described [47]. Briefly, cells were seeded in 6 well plates at 
the specified numbers and then exposed to X-ray irradiation 
using a Faxitron RX-650 apparatus (100 kVp, 1.14 Gy/min; 
Faxitron Bioptics). After incubating for 10 days, cells 
were fixed with methanol and stained with crystal violet. 
Colonies comprising at least 50 cells were counted. The 
surviving fraction of irradiated cells was normalized to that 
of the corresponding unirradiated Controls.
Immunoblotting
Immunoblotting was performed as previously 
described [48]. The following antibodies were purchased 
from Cell Signaling Technology: SMAD4 (38454) and 
β-actin (3700). Uncropped versions of the immunoblots 
are shown in Supplementary Figure 6.
Statistical analysis
Differences in SF2 between two groups were 
examined as follows: First, normality was confirmed using 
the Shapiro-Wilk test. Next, variance was examined using an 
F test. Differences between two groups with equal variance 
were examined using Student’s t-test. Differences between 
groups without equal variance were examined using Welch’s 
t-test. Differences in the distribution of cancer type between 
the KRASmt/SMAD4mt cell lines and Control cell lines were 
examined using Fisher’s exact test. All statistical analyses 
were performed using Prism 6 (GraphPad) or EZR (Saitama 
Medical Center), which is a graphical user interface for R 
ver. 3.3.2 (The R Foundation for Statistical Computing) [49]. 
A P value < 0.05 was considered significant.
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